TrialMedical oncology (Northwood, London, England)2013

Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.

Jordi Codony-Servat et al.PubMed ↗Publisher ↗

No numbers read from the abstract.